Skip to content Accessibility statement

New genetic map will speed up plant breeding of the world's most important medicinal crop

Posted on 14 January 2010

Plant scientists at the University of York have published the first genetic map of the medicinal herb Artemisia annua.

The map is being used to accelerate plant breeding of Artemisia and rapidly develop the species into a high-yielding crop. This development is urgently needed to help meet escalating demand for effective malaria treatments.

Though preventable and treatable, malaria is a serious global health problem, estimated to kill almost a million people every year. The most effective drugs for treating malaria are Artemisinin Combination Therapies (ACTs). Increased funding for malaria treatments means demand for ACTs is expected to double from last year’s figures, to around 200 million treatments, by 2012. However, meeting this increased demand will be a challenge: artemisinin is extracted from the plant Artemisia annua, but yields are low, making production expensive. In recent years, Artemisia production has been uneconomic and planting areas have declined, raising fears of shortages.

Plant scientists at the Centre for Novel Agricultural Products (CNAP) in the Department of Biology at the University of York are addressing this problem by using molecular technologies to rapidly improve the Artemisia crop. In the latest issue of Science, they publish the first genetic map of this species, plotting the location on the plant’s genome of genes, traits and markers associated with high performance. This will enable scientists to recognise young plants as high performers from their genetics. It will also inform the selection of suitable parent plants for breeding experiments.

With our new understanding of Artemisia genetics, we can produce improved, non-GM varieties of Artemisia much faster than would otherwise be possible

Professor Ian Graham

The map has been validated in glasshouse experiments that found the top-performing plants had elevated frequencies of genetic indicators for high yield. The project is led by Professor Dianna Bowles and Professor Ian Graham. Professor Graham says “The map is already proving to be an essential tool for us. With our new understanding of Artemisia genetics, we can produce improved, non-GM varieties of Artemisia much faster than would otherwise be possible.” This speed is essential. “We intend to get high-yielding seed to farmers in the next 2-3 years in order to supply soaring demand for malaria treatments” explains Professor Dianna Bowles. “This is a really tight deadline and we can only do it with the benefit of the new knowledge provided by the map.” The work demonstrates how modern genetics is shortening the timescales needed to turn a wild plant species into a domesticated crop.

The scientists at York are creating the new varieties for use by many thousands of small scale growers in the developing world, for whom the Artemisia crop is an important source of income. The project has just received its second grant from the Bill & Melinda Gates Foundation. This grant will support final development of the new varieties and their delivery to Artemisia producers in Africa and Asia.

ENDS

Notes to editors:

  • “The genetic map of Artemisia annua L. identifies multiple loci affecting yield of the antimalarial drug artemisinin” by Ian A. Graham et al. appears in Science on Friday, 15 January.
  • More information on the project can be found at; www.york.ac.uk/org/cnap/artemisiaproject/index.htm
  • The Centre for Novel Agricultural Products (CNAP) is a research centre in the Department of Biology at the University of York. Its mission is to realise the potential of plant- and microbial-based renewable resources through gene discovery and germplasm
  • The work is funded by The Bill & Melinda Gates Foundation. It builds on work financed by the Medicines for Malaria Venture and GlaxoSmithKline, and supported by core-funding to CNAP from the Garfield Weston Foundation.
  • Estimates of future ACT demand and artemisinin supply can be found in a recent scenario analysis by the Boston Consulting Group; http://www.york.ac.uk/org/cnap/artemisiaproject/work%20docs/Artemisinin%20Scenario%20Analysis.pdf
  • Images are available on request from Elspeth Bartlet
  • For more information, please contact; Dr Elspeth Bartlet, External Communications Manager, The CNAP Artemisia Research Project. Tel:      +44 (0)1904 32 8834; Mobile  +44 (0) 7814664961 eb526@york.ac.uk

Contact details

Elspeth Bartlet

Tel: +44 (0)1904 32 8834
or +44 (0) 7814664961

eb526@york.ac.uk

Keep up to date

 Subscribe to news feeds

 Follow us on Twitter

Audio